Fig. 6

Effect of GSNO pretreatment on intestinal epithelial barrier. In vitro, EGCs-conditioned medium was collected to measure the GSNO level (a) (n = 6). The levels of ZO-1 and occludin expression in Caco-2 cells were evaluated by western blot after the stimulation of EGCs-conditioned medium with or without GSNO 50 µM) supplementation (b, c) (n = 6). In vivo, GSNO was administrated intraperitoneally at 10 mg/kg/day for 7 days before CLP. 24 h after CLP, mice were sacrificed, and tissue samples were collected. d The survival percentage of the mice was investigated within 7 days after CLP by survival curves (n = 10). Intestinal barrier permeability was indicated by serum FITC-Dextran levels (e) (n = 6), water content (f) of gut (n = 6), and colony-forming units (CFUs) (g–i) from mesenteric lymph node (MLN), liver and lung (n = 6). The data are presented as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001